Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""olanzapine"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 736
Tytuł:
The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.
Autorzy:
Arnaiz JA; Phase I Unit, Clinical Pharmacology Department, Hospital Clinic de Barcelona (HCB), Barcelona, Spain.; Department of Basic Clinical Practice, University of Barcelona (UB), Casanova 143, E-08036, Barcelona, Spain.
Rodrigues-Silva C; Department of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil.
Mezquida G; Department of Basic Clinical Practice, University of Barcelona (UB), Casanova 143, E-08036, Barcelona, Spain.; Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, HCB, Barcelona, Catalunya, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain.
Amoretti S; Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, HCB, Barcelona, Catalunya, Spain.; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain.
Cuesta MJ; Departmentof Psychiatry, Complejo Hospitalario de Navarra, Instituto de Investigaciones Sanitarias de Navarra (IdiSNa), Pamplona, Spain.
Fraguas D; Institute of Psychiatry and Mental Health, Hospital Clínico San Carlos, IdISSC, CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain.
Lobo A; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Department of Medicine and Psychiatry, Zaragoza University, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain.
González-Pinto A; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Hospital Universitario Araba, Servicio de Psiquiatria, UPV/EHU, Bioaraba, Spain.
Díaz-Caneja MC; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañon, CIBERSAM, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.
Corripio I; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Psychiatry Department, Institut d'Investigació Biomèdica-Sant Pau (IIB-SANT PAU), Hospital de la Santa Creu i Sant Pau; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Vieta E; Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.
Baeza I; Department of Child and Adolescent Psychiatry and Psychology, Clínic Institute of Neurosciences, Hospital Clínic de Barcelona, 2017SGR881, University of Barcelona, CIBERSAM, IDIBAPS, Barcelona, Spain.
Mané A; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.; Autonomous university of Barcelona (UAB), Barcelona, Spain.
García-Rizo C; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain.; Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, Hospital Clínic of Barcelona, Barcelona, Spain.; Department of Medicine, Barcelona, UB, Spain.
Bioque M; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain.; Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, Hospital Clínic of Barcelona, Barcelona, Spain.; Department of Medicine, Barcelona, UB, Spain.
Saiz J; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Department of Psychiatry, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain.
Bernardo M; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain.; Barcelona Clínic Schizophrenia Unit, Neuroscience Institute, Hospital Clínic of Barcelona, Barcelona, Spain.; Department of Medicine, Barcelona, UB, Spain.
Mas S; Department of Basic Clinical Practice, University of Barcelona (UB), Casanova 143, E-08036, Barcelona, Spain. .; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain. .; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain. .
Pokaż więcej
Corporate Authors:
PEPs group
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2021 Mar; Vol. 238 (3), pp. 665-676. Date of Electronic Publication: 2020 Nov 23.
Typ publikacji:
Journal Article
MeSH Terms:
Antipsychotic Agents/*blood
Drug Monitoring/*methods
Olanzapine/*blood
Psychotic Disorders/*drug therapy
Adult ; Antipsychotic Agents/therapeutic use ; Blood Glucose/analysis ; Blood Pressure/drug effects ; Female ; Humans ; Male ; Middle Aged ; Olanzapine/therapeutic use ; Psychotic Disorders/blood ; Psychotic Disorders/psychology ; Smoking/blood ; Treatment Outcome ; Weight Gain/drug effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gain.
Autorzy:
Schreyer KF; Department of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany. .
Leucht S; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Heres S; kbo-Klinik für Psychiatrie und Psychotherapie Nord - Schwabing, Kölner Platz 1, 80804, Munich, Germany.
Steimer W; Department of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2023 Apr; Vol. 240 (4), pp. 899-908. Date of Electronic Publication: 2023 Feb 09.
Typ publikacji:
Randomized Controlled Trial; Multicenter Study; Journal Article
MeSH Terms:
Antipsychotic Agents*/therapeutic use
Humans ; Amisulpride ; Genome-Wide Association Study ; Olanzapine ; Polymorphism, Single Nucleotide ; Weight Gain
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Coadministration of metformin prevents olanzapine-induced metabolic dysfunction and regulates the gut-liver axis in rats.
Autorzy:
Luo C; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China.; School of Life Sciences, Central South University, Changsha, 410078, Hunan, China.
Wang X; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China.
Huang HX; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China.
Mao XY; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China.
Zhou HH; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China.
Liu ZQ; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. .; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, People's Republic of China. .
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2021 Jan; Vol. 238 (1), pp. 239-248. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji:
Journal Article
MeSH Terms:
Adjuvants, Pharmaceutic/*pharmacology
Gastrointestinal Microbiome/*drug effects
Liver/*drug effects
Metabolic Diseases/*prevention & control
Metformin/*pharmacology
Olanzapine/*adverse effects
Adjuvants, Pharmaceutic/administration & dosage ; Animals ; Bacteroides/isolation & purification ; Blood Glucose/metabolism ; Body Weight/drug effects ; Dose-Response Relationship, Drug ; Feces/microbiology ; Humans ; Lactobacillus gasseri/isolation & purification ; Liver/metabolism ; Male ; Metabolic Diseases/chemically induced ; Metformin/administration & dosage ; Olanzapine/administration & dosage ; RNA, Ribosomal, 16S/genetics ; Rats
SCR Organism:
Bacteroides acidifaciens
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.
Autorzy:
Jena M; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Mishra A; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Mishra BR; Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Nath S; Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
Maiti R; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India. pharm_.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2020 Nov; Vol. 237 (11), pp. 3471-3480. Date of Electronic Publication: 2020 Aug 01.
Typ publikacji:
Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:
Antipsychotic Agents/*therapeutic use
Cardiovascular Diseases/*blood
Lurasidone Hydrochloride/*therapeutic use
Metabolic Diseases/*blood
Olanzapine/*therapeutic use
Schizophrenia/*blood
Adult ; Antipsychotic Agents/adverse effects ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Cardiovascular Diseases/chemically induced ; Cardiovascular Diseases/epidemiology ; Female ; Follow-Up Studies ; Humans ; Lipids/blood ; Lurasidone Hydrochloride/adverse effects ; Male ; Metabolic Diseases/chemically induced ; Metabolic Diseases/epidemiology ; Middle Aged ; Olanzapine/adverse effects ; Schizophrenia/drug therapy ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Long-term effects of adolescent exposure to olanzapine in C57BL/6 J mice and the impact of dietary fish oil supplementation.
Autorzy:
Soto PL; Department of Psychology, Louisiana State University, Baton Rouge, LA, 70803, USA. .; Pennington Biomedical Research Center, Baton Rouge, LA, 70808, USA. .
Ramalingam L; Department of Nutritional Sciences and Obesity Research Institute, Texas Tech University, Lubbock, TX, 79409, USA.; Department of Nutrition and Food Studies, Syracuse University, Syracuse, NY, 13210, USA.
George B; Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC, 27101, USA.
Moustaid-Moussa N; Department of Nutritional Sciences and Obesity Research Institute, Texas Tech University, Lubbock, TX, 79409, USA.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2022 Oct; Vol. 239 (10), pp. 3117-3131. Date of Electronic Publication: 2022 Jul 27.
Typ publikacji:
Journal Article
MeSH Terms:
Antipsychotic Agents*/pharmacology
Animals ; Diet, High-Fat/adverse effects ; Dietary Supplements ; Fatty Acids ; Female ; Fish Oils/pharmacology ; Male ; Mice ; Mice, Inbred C57BL ; Olanzapine ; Sugars ; Weight Gain
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years.
Autorzy:
Hong Y; Physical Education Department, Chengdu Sport University, Chengdu, Sichuan, China.
Huang W; Clinical Translational Science, Juntendo University Graduate School of Medicine, Bunkyo City, 2 Chome-1-1 Hongo, Tokyo, 113-8421, Japan. .
Cao D; Department of Physical Education, Southwest University, Chongqing, China.
Xu J; Department of Rehabilitation Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Wei H; Sports Department, Nanchang Institute of Science and Technology, Nanchang, Jiangxi, China.
Zhang J; Medical & Nursing School, Chengdu University, Chengdu, Sichuan, China.
Wang L; Department of Physical Education, Hebei Institute of Physical Education, Shijiazhuang, Hebei, China.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2022 Oct; Vol. 239 (10), pp. 3367-3375. Date of Electronic Publication: 2022 Sep 05.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Antimanic Agents*/adverse effects
Antipsychotic Agents*/therapeutic use
Adult ; Aripiprazole ; Benzodiazepines/therapeutic use ; Carbamazepine ; Dibenzocycloheptenes ; Haloperidol/therapeutic use ; Humans ; Lithium ; Mania ; Network Meta-Analysis ; Olanzapine ; Paliperidone Palmitate ; Pharmaceutical Preparations ; Piperazines ; Quetiapine Fumarate ; Risperidone/therapeutic use ; Tamoxifen ; Thiazoles ; Valproic Acid/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Association between depression in chronic phase and future clinical outcome of patients with schizophrenia.
Autorzy:
Yamada, Yuto (AUTHOR)
Yamauchi, Yusuke (AUTHOR)
Sakamoto, Shinji (AUTHOR)
Fujiwara, Masaki (AUTHOR)
Okahisa, Yuko (AUTHOR)
Takao, Soshi (AUTHOR)
Takaki, Manabu (AUTHOR)
Yamada, Norihito (AUTHOR)
Pokaż więcej
Źródło:
Psychopharmacology. Mar2022, Vol. 239 Issue 3, p965-975. 11p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients.
Autorzy:
Huang J; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiao J; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Peng Z; Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Shao P; Department of Psychiatry, The Second People's Hospital of Hunan Province, Changsha, Hunan, China.
Sun M; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Long Y; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Wang X; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Shen M; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Kang D; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yang Y; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Peng X; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Wang W; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xie P; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Shao T; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Zhao J; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Wu R; National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China. .; Department of Psychiatry, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China. .
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2022 Jan; Vol. 239 (1), pp. 83-91. Date of Electronic Publication: 2022 Jan 14.
Typ publikacji:
Journal Article
MeSH Terms:
Dyslipidemias*/chemically induced
Schizophrenia*/drug therapy
Animals ; Humans ; Mice ; Olanzapine ; Proprotein Convertase 9
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effect of Bifidobacterium on olanzapine-induced body weight and appetite changes in patients with psychosis.
Autorzy:
Yang Y; National Clinical Research Center for Mental Disorders, and Department of Psychiatry, The Second Xiangya Hospital of Central South University, 410011, Hunan, China.
Long Y; National Clinical Research Center for Mental Disorders, and Department of Psychiatry, The Second Xiangya Hospital of Central South University, 410011, Hunan, China.
Kang D; National Clinical Research Center for Mental Disorders, and Department of Psychiatry, The Second Xiangya Hospital of Central South University, 410011, Hunan, China.
Liu C; National Clinical Research Center for Mental Disorders, and Department of Psychiatry, The Second Xiangya Hospital of Central South University, 410011, Hunan, China.
Xiao J; National Clinical Research Center for Mental Disorders, and Department of Psychiatry, The Second Xiangya Hospital of Central South University, 410011, Hunan, China.
Wu R; National Clinical Research Center for Mental Disorders, and Department of Psychiatry, The Second Xiangya Hospital of Central South University, 410011, Hunan, China. .
Zhao J; National Clinical Research Center for Mental Disorders, and Department of Psychiatry, The Second Xiangya Hospital of Central South University, 410011, Hunan, China.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2021 Sep; Vol. 238 (9), pp. 2449-2457. Date of Electronic Publication: 2021 May 17.
Typ publikacji:
Journal Article
MeSH Terms:
Antipsychotic Agents*/therapeutic use
Psychotic Disorders*/drug therapy
Appetite/drug effects ; Benzodiazepines/pharmacology ; Bifidobacterium ; Body Mass Index ; Body Weight/drug effects ; Humans ; Olanzapine/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A potential probiotic bacterium for antipsychotic-induced metabolic syndrome: mechanisms underpinning how Akkermansia muciniphila subtype improves olanzapine-induced glucose homeostasis in mice.
Autorzy:
Huang D; Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Gao J; Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Li C; Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Nong C; Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Huang W; Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Zheng X; Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Li S; Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China.
Peng Y; Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. .; Department of Transfusion Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, Guangdong, China. .
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2021 Sep; Vol. 238 (9), pp. 2543-2553. Date of Electronic Publication: 2021 May 27.
Typ publikacji:
Journal Article
MeSH Terms:
Antipsychotic Agents*
Probiotics*
Metabolic Syndrome/*drug therapy
Akkermansia ; Animals ; Base Composition ; Female ; Glucose ; Homeostasis ; Metabolic Syndrome/chemically induced ; Mice ; Mice, Inbred C57BL ; Olanzapine ; Phylogeny ; RNA, Ribosomal, 16S ; Sequence Analysis, DNA
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Evaluation of dopamine D 3 receptor occupancy by blonanserin using [ C]-(+)-PHNO in schizophrenia patients.
Autorzy:
Sakayori T; Department of Neuropsychiatry, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Tateno A; Department of Neuropsychiatry, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Arakawa R; Department of Neuropsychiatry, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Kim WC; Department of Neuropsychiatry, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Okubo Y; Department of Neuropsychiatry, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan. .
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2021 May; Vol. 238 (5), pp. 1343-1350. Date of Electronic Publication: 2020 Nov 12.
Typ publikacji:
Journal Article
MeSH Terms:
Piperazines/*pharmacology
Piperidines/*pharmacology
Receptors, Dopamine D2/*metabolism
Receptors, Dopamine D3/*metabolism
Schizophrenia/*drug therapy
Adult ; Aged ; Antipsychotic Agents/therapeutic use ; Cross-Over Studies ; Female ; Humans ; Male ; Middle Aged ; Olanzapine/therapeutic use ; Positron-Emission Tomography/methods ; Putamen/metabolism ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting
Autorzy:
Hosokawa, TomonariAff1, Aff2
Miyaji, Chikara
Yoshimura, Yusaku
Washida, Kenji
Yada, Yuji
Sakamoto, Shinji
Okahisa, Yuko
Takao, Soshi
Nomura, Akira
Kishi, Yoshiki
Harada, Toshiki
Takaki, ManabuAff1, IDs00213023064076_cor12
Takeda, Toshihiko
Yamada, Norihito
Pokaż więcej
Źródło:
Psychopharmacology. 240(9):1911-1920
Czasopismo naukowe
Szczegóły
Tytuł:
Hippocampal and prefrontal cortical NMDA receptors mediate the interactive effects of olanzapine and lithium in memory retention in rats: the involvement of CAMKII-CREB signaling pathways.
Autorzy:
Amiri S; Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Jafari-Sabet M; Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. .; Razi Drug Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. .
Keyhanfar F; Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Falak R; Immunology Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Shabani M; Kerman Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.
Rezayof A; Department of Animal Biology, School of Biology and Center of Excellence in Phylogeny of Living Organisms, College of Science, University of Tehran, Tehran, Iran.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2020 May; Vol. 237 (5), pp. 1383-1396. Date of Electronic Publication: 2020 Jan 27.
Typ publikacji:
Journal Article
MeSH Terms:
Calcium-Calmodulin-Dependent Protein Kinase Type 2/*metabolism
Cyclic AMP Response Element-Binding Protein/*metabolism
Lithium Carbonate/*administration & dosage
Memory Consolidation/*physiology
Olanzapine/*administration & dosage
Receptors, N-Methyl-D-Aspartate/*metabolism
Animals ; Avoidance Learning/drug effects ; Avoidance Learning/physiology ; Dizocilpine Maleate/pharmacology ; Dose-Response Relationship, Drug ; Drug Synergism ; Hippocampus/drug effects ; Hippocampus/metabolism ; Male ; Memory Consolidation/drug effects ; Prefrontal Cortex/drug effects ; Prefrontal Cortex/metabolism ; Rats ; Rats, Wistar ; Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors ; Signal Transduction/drug effects ; Signal Transduction/physiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome.
Autorzy:
Skonieczna-Żydecka K; Department of Biochemistry and Human Nutrition, Pomeranian Medical University, Szczecin, Poland. .
Łoniewski I; Department of Biochemistry and Human Nutrition, Pomeranian Medical University, Szczecin, Poland.; Sanprobi sp. z o.o. sp. k, Szczecin, Poland.
Misera A; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.
Stachowska E; Department of Biochemistry and Human Nutrition, Pomeranian Medical University, Szczecin, Poland.
Maciejewska D; Department of Biochemistry and Human Nutrition, Pomeranian Medical University, Szczecin, Poland.
Marlicz W; Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland.
Galling B; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.; The Zucker Hillside Hospital, Psychiatry Research, Northwell Health,, Glen Oaks, NY, USA.; Hofstra Northwell School of Medicine, Hofstra University, Hempstead, NY, USA.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2019 May; Vol. 236 (5), pp. 1491-1512. Date of Electronic Publication: 2018 Nov 20.
Typ publikacji:
Journal Article; Systematic Review
MeSH Terms:
Antipsychotic Agents/*adverse effects
Gastrointestinal Microbiome/*drug effects
Metabolic Diseases/*chemically induced
Metabolic Diseases/*metabolism
Weight Gain/*drug effects
Animals ; Antipsychotic Agents/therapeutic use ; Benzodiazepines/adverse effects ; Benzodiazepines/therapeutic use ; Gastrointestinal Microbiome/physiology ; Humans ; Hyperglycemia/chemically induced ; Hyperglycemia/metabolism ; Olanzapine/adverse effects ; Olanzapine/therapeutic use ; Risperidone/adverse effects ; Risperidone/therapeutic use ; Weight Gain/physiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole.
Autorzy:
Obayashi Y; Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.; Department of Psychiatry, Okayama Psychiatric Medical Center, Okayama, Japan.; Department of Psychiatry, Zikei Hospital, Okayama, Japan.; Department of Psychiatry, Fukuyama Kokorono Hospital, Fukuyama, Japan.
Mitsui S; Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Sakamoto S; Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Minao N; Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yoshimura B; Department of Psychiatry, Okayama Psychiatric Medical Center, Okayama, Japan.
Kono T; Department of Psychiatry, Okayama Psychiatric Medical Center, Okayama, Japan.
Yada Y; Department of Psychiatry, Okayama Psychiatric Medical Center, Okayama, Japan.
Okahisa Y; Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Takao S; Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kishi Y; Department of Psychiatry, Okayama Psychiatric Medical Center, Okayama, Japan.
Takeda T; Department of Psychiatry, Zikei Hospital, Okayama, Japan.
Takaki M; Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. .
Yamada N; Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2020 Jan; Vol. 237 (1), pp. 167-175. Date of Electronic Publication: 2019 Oct 18.
Typ publikacji:
Journal Article
MeSH Terms:
Antipsychotic Agents/*therapeutic use
Aripiprazole/*therapeutic use
Schizophrenia/*drug therapy
Adult ; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Olanzapine/therapeutic use ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial.
Autorzy:
Fan X; Psychotic Disorders Program, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, 01605, USA. .
Copeland P; Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Nawras S; Psychotic Disorders Program, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, 01605, USA.
Harrington A; Psychotic Disorders Program, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, 01605, USA.
Freudenreich O; Schizophrenia Program, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Goff DC; Department of Psychiatry, New York University Medical School and Nathan Kline Institute, New York, NY, USA.
Henderson DC; Department of Psychiatry, Boston University/Boston Medical Center, Boston, MA, USA.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2019 Jun; Vol. 236 (6), pp. 1949-1957. Date of Electronic Publication: 2019 Feb 12.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Antipsychotic Agents/*administration & dosage
Clozapine/*administration & dosage
Olanzapine/*administration & dosage
Schizophrenia/*drug therapy
Schizophrenia/*metabolism
Telmisartan/*administration & dosage
Adult ; Body Composition/drug effects ; Body Composition/physiology ; Body Mass Index ; Body Weight/drug effects ; Body Weight/physiology ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Glucose/metabolism ; Humans ; Insulin/blood ; Male ; Middle Aged ; Treatment Outcome ; Triglycerides/blood
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial.
Autorzy:
Xu F; Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Fan W; Department of Psychiatry, Jinhua Second Hospital, Jinhua, Zhejiang, China.
Wang W; Department of Psychiatry, Jinhua Second Hospital, Jinhua, Zhejiang, China.
Tang W; Department of Psychiatry, Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yang F; Department of Psychiatry, Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.; Shanghai Key Laboratory of Brain Functional Genomics (Ministry of Education), School of Psychology and Cognitive Science, East China Normal University, Shanghai, China.
Zhang Y; Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cai J; Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Song L; Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhang C; Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. .; Department of Psychiatry, Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. .
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2019 Apr; Vol. 236 (4), pp. 1273-1279. Date of Electronic Publication: 2018 Dec 05.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Dietary Supplements*
Fatty Acids, Omega-3/*therapeutic use
Metabolic Syndrome/*drug therapy
Metabolic Syndrome/*epidemiology
Schizophrenia/*drug therapy
Schizophrenia/*epidemiology
Adult ; Antipsychotic Agents/therapeutic use ; Biomarkers/blood ; Female ; Humans ; Male ; Metabolic Syndrome/blood ; Middle Aged ; Olanzapine/urine ; Schizophrenia/blood ; Time Factors ; Treatment Outcome ; Triglycerides/blood ; Tumor Necrosis Factor-alpha/blood
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
Autorzy:
Smith RC; Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA. .; Department of Psychiatry, NYU Langone Medical Center, New York, NY, USA. .
Maayan L; Albany Medical College, Albany, NY, USA.
Wu R; Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, and Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Youssef M; Harlem Hospital, Columbia University, New York, NY, USA.
Jing Z; Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, and Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Sershen H; Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA.; Department of Psychiatry, NYU Langone Medical Center, New York, NY, USA.
Szabo V; Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA.
Meyers J; Oregon Health and Science University, Portland, OR, USA.
Jin H; University of California San Diego, Department of Psychiatry, San Diego, and VA San Diego Healthcare System, San Diego, CA, USA.
Zhao J; Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, and Mental Health Institute of the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Davis JM; Psychiatric Institute University of Illinois, Chicago, Illinois and John Hopkins University Medical School, Baltimore, USA.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2018 Dec; Vol. 235 (12), pp. 3545-3558. Date of Electronic Publication: 2018 Oct 31.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antipsychotic Agents/*adverse effects
Betahistine/*therapeutic use
Body Weight/*drug effects
Histamine Agonists/*therapeutic use
Schizophrenia/*drug therapy
Weight Gain/*drug effects
Adolescent ; Adult ; Antipsychotic Agents/therapeutic use ; Betahistine/pharmacology ; Body Mass Index ; Body Weight/physiology ; Child ; Clozapine/adverse effects ; Clozapine/therapeutic use ; Double-Blind Method ; Female ; Histamine Agonists/pharmacology ; Humans ; Male ; Olanzapine/adverse effects ; Olanzapine/therapeutic use ; Schizophrenia/blood ; Treatment Outcome ; Weight Gain/physiology ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Autorzy:
Smith RC; Department of Psychiatry, New York University School of Medicine, New York, NY, USA. .; Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA. .
Leucht S; Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany.
Davis JM; Department of Psychiatry, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pokaż więcej
Źródło:
Psychopharmacology [Psychopharmacology (Berl)] 2019 Feb; Vol. 236 (2), pp. 545-559. Date of Electronic Publication: 2018 Nov 30.
Typ publikacji:
Journal Article; Meta-Analysis; Review
MeSH Terms:
Schizophrenic Psychology*
Antipsychotic Agents/*therapeutic use
Schizophrenia/*drug therapy
Amisulpride/therapeutic use ; Antidepressive Agents/therapeutic use ; Clozapine/therapeutic use ; Depression/drug therapy ; Depression/psychology ; Humans ; Imidazoles/therapeutic use ; Indoles/therapeutic use ; Olanzapine/therapeutic use ; Piperazines/therapeutic use ; Risperidone/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 736

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies